Genmab buys ADC technology license from Synaffix

Genmab will pay USD 4.5m upfront for access to antibody technologies developed by Synaffix, in a deal that could total up to USD 415m.

Photo: Tuala Hjarnø / Genmab / PR

A new licensing agreement will secure Genmab the right to use technologies developed by Dutch biotech company Synaffix.

Synaffix offers several ADC (antibody-drug conjugate) technologies, which according to a press release from the company, offer a "rapid timeline to clinic."

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Rumored GN purchase unlikely but not impossible, say analysts

A low value assessment, a high structural value, and no dominant shareholders make GN Group a reasonable investment case for international private equity firms and industrial players. But just how likely is it? Analysts reveal their best bets for what a GN acquisition could look like.

New CFO wants to shake things up at WSA

A mere month into her new job, Marianne Wiinholt, WS Audiology’s fifth chief financial officer since the firm was established through a merger in 2019, is heralding great structural changes.

Further reading

Related articles

Latest news

See all jobs